Why GlaxoSmithKline plc Is More Like Unilever plc Than AstraZeneca plc

The investment characteristics of GlaxoSmithKline plc (LON:GSK) are more like Unilever plc (LON:ULVR) than sector peer AstraZeneca plc (LON:AZN)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It used to be that investors in big pharma had a straight choice between GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) and AstraZeneca (LSE:AZN) (NYSE: AZN.US). They remain the two largest firms in the pharmaceutical sector of the London Stock Exchange, so that thinking still lingers in most investors’ minds.

But GSK’s CEO Andrew Witty has taken his company in a very different direction from Pascal Soriot at Astra. The two companies are no longer comparable, and it distorts the investment case to think of them that way.

The Unilever of healthcare

Mr Witty has de-emphasised the traditional big pharma strategy, whereby massive up-front investment in R&D aims to discover the next blockbuster drug to fund years of fat profits — most notably through the recent asset-swap with Novartis. He argues that Western governments will eventually baulk at the cost of healthcare for an ageing population, so the next generation of drugs won’t be so profitable. Perhaps the recent patent cliff scare also underlined the risky nature of prescription medicine.

So Mr Witty is emphasising global distribution of branded over-the-counter products and lower-margin vaccines, both of which play into growth in emerging market demand. Global consumer brands, low margins, emerging market growth, that sounds like the Unilever (LSE: ULVR) of healthcare. The two companies’ products even meet tangentially: there are markets where Unilever’s Signal toothpaste is up against GSK’s Aquafresh. The transition of GSK’s Horlicks from a Victorian tonic to India’s leading health drink mirrors the trajectory of Unilever’s Lifebuoy soap.

Biotech with a dividend

When Pascal Soriot took the helm in 2012 he committed AstraZeneca to just the science-heavy, R&D-led drug development that Andrew Witty is turning away from. Facing a steep and treacherous patent cliff, at the time I described Astra as like a biotech company with a dividend attached.

It still is, but three things have played to Mr Soriot’s advantage. To his credit, Astra’s scientists are delivering. Right now it’s creating a stir with immunotherapy, especially as a cancer cure. Secondly, biotech has become a fashionable sector. The thinking is that if you invent the drug, someone will pay for it. Thirdly, Pfizer’s aborted bid boosted Astra’s share price, which has remained elevated on the back of Mr Soriot’s bold confidence in Astra’s standalone earnings potential.

And the winner is…

Which of Mr Witty and Mr Soriot will eventually be proved right? The lesson for investors is that we won’t know until it’s too late. Investors shouldn’t stake too much on guessing what the future holds. Rather they should pick stocks — and plan portfolios — to suit their circumstances.

Personally I like boring but safe GSK. Stocks like GSK and Unilever, which offer bond-like security in their payout whilst locking in emerging market growth, make good cornerstone shares.

I’m wary of Astra’s valuation. Buoyed by lingering bid hopes, Mr Soriot’s big promises, and a biotech sector that could be in a bubble, I perceive bigger downside risk in the share price — but that’s countered by a bigger potential upside.

High yield

Both Astra and GSK offer good dividend yields, if little in the way of near-term dividend growth. That underlines their attraction to many investors, whether you want the income or want to re-invest and enjoy the compound growth in your holding.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony Reading owns shares in GlaxoSmithKline and Unilever. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »